Issues related to the FDA and treatment for rare disease
2025 · 1st Quarter (Jan 1 - Mar 31)
OMEROS CORPORATION
Filed by AVENUE SOLUTIONS.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Termination
- Posted
- Jul 21, 2025
- Income
- $80,000.00
- Expenses
- Not reported
- Registrant
- AVENUE SOLUTIONS
- Client
- OMEROS CORPORATION
- Filing UUID
- 5f07830b-1d71-4ecd-b89b-51aa5a582955
- Termination date
- Mar 31, 2025
Literal source text
Lobbying issues and bill citations
Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; S. 891, Bipartisan Health Care Act; H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4)
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.